{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:41:56Z","timestamp":1790804516345,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1704,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1177\/0091270010363477","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T03:00:52Z","timestamp":1269313252000},"page":"93-101","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis"],"prefix":"10.1002","volume":"51","author":[{"given":"Joan M.","family":"Korth-Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Baird-Bellaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain A.","family":"Patat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Troy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele M.","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph H.","family":"Gleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhild","family":"Buecheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha Y.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"10.1177\/0091270010363477-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1242\/jcs.00365","article-title":"Antibiotics action on the translational machinery","volume":"11","author":"Harms","year":"2003","journal-title":"J Cell Sci"},{"key":"10.1177\/0091270010363477-BIB2|cit2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1177\/0091270010363477-BIB3|cit3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1368-7646(02)00051-1","article-title":"New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors","volume":"5","author":"Chopra","year":"2002","journal-title":"Drug Resist Updat"},{"key":"10.1177\/0091270010363477-BIB4|cit4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/AAC.39.1.247","article-title":"A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline\/H+ antiporter","volume":"39","author":"Someya","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1177\/0091270010363477-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1128\/AAC.38.7.1658","article-title":"Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines","volume":"38","author":"Rasmussen","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1177\/0091270010363477-BIB6|cit6","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clinical Infectious Disease"},{"key":"10.1177\/0091270010363477-BIB7|cit7","volume-title":"Tygacil [package insert]","year":"2009"},{"key":"10.1177\/0091270010363477-BIB8|cit8","doi-asserted-by":"crossref","first-page":"S12.22","DOI":"10.1179\/joc.2005.17.Supplement-1.12","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of tigecycline","volume":"17","author":"Rello","year":"2005","journal-title":"J Chemother"},{"key":"10.1177\/0091270010363477-BIB9|cit9","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1128\/AAC.01636-05","article-title":"Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections","volume":"50","author":"Wart","year":"2006","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1177\/0091270010363477-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.107.015735","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects","volume":"35","author":"Hoffmann","year":"2007","journal-title":"Drug Metabol Dispos"},{"key":"10.1177\/0091270010363477-BIB11|cit11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s005340200055","article-title":"Hepatobiliary transport of bile acids and organic anions","volume":"9","author":"Takikawa","year":"2002","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1177\/0091270010363477-BIB12|cit12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1177\/0091270010363477-BIB13|cit13","unstructured":"US Department of Health and Human Services, FDA, CDER, CBER Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling 2003 http:www.fda.govDrugsGuidanceComplianceRegulatoryInformationGuidancesucm064982.htm"},{"key":"10.1177\/0091270010363477-BIB14|cit14","unstructured":"EMEA, CHMP, Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function 2005 http:www.emea.europa.euhtmshumanhumanguidelinesefficacy.htm"},{"key":"10.1177\/0091270010363477-BIB15|cit15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.phrs.2004.03.002","article-title":"No influence of moderate hepatic impairment on the pharmacokinetics of lumiacoxib, an oral COX-2 selective inhibitor","volume":"50","author":"Kalbag","year":"2004","journal-title":"Pharm Res"},{"key":"10.1177\/0091270010363477-BIB16|cit16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Agent Chemother"},{"key":"10.1177\/0091270010363477-BIB17|cit17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutical drug disposition classification system (BDDCS)","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"10.1177\/0091270010363477-BIB18|cit18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejps.2005.12.007","article-title":"Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanism of hepatic excretion of sulfate, glucuronide, and glutathione metabolites","volume":"27","author":"Zamek-Gliszczynski","year":"2006","journal-title":"Eur J Pharm Science"},{"key":"10.1177\/0091270010363477-BIB19|cit19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010363477-BIB20|cit20","volume-title":"Handbook of Pharmacokinetics: Toxicity Assessment of Chemicals","author":"Labaume","year":"1989"},{"key":"10.1177\/0091270010363477-BIB21|cit21","volume-title":"Toxicodynamic analyses of tigecycline in patients with hospital associated pneumonia (HAP) or community acquired pneumonia (CAP)","author":"Rubino","year":"2007"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010363477","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1177\/0091270010363477\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:57:06Z","timestamp":1657803426000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010363477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010363477","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}